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ConfBackground: Patients with cutaneous melanoma metastases have experienced excellent responses to
intralesional interleukin (IL)-2. This has led to its recent inclusion into the US National Comprehensive
Cancer Network guidelines for management of cutaneous melanoma metastases. Despite this, intralesional
IL-2 has not been highlighted in the US literature nor have US physicians adopted it.Objective: We sought to evaluate the effectiveness of intralesional IL-2 combined with topical imiquimod
and retinoid for treatment of cutaneous metastatic melanoma.Methods: A retrospective case series of 11 patients with cutaneous metastatic melanoma were treated with
intralesional IL-2 combined with topical imiquimod and retinoid.Results: A 100% complete local response rate with long-term follow-up (average of 24 months) was seen
in all 11 patients treated with this proposed regimen. Biopsy specimens of treated sites confirmed absence
of malignant cells. The most common treatment-related adverse event was rigors.Limitations: Small number of patients, retrospective review of charts, and lack of a comparison group
were limitations.Conclusion: Intralesional IL-2 administered concomitantly with topical imiquimod and a retinoid cream is
a promising therapeutic option for managing cutaneous melanoma metastases. The regimen was well
tolerated and should be considered as a reasonable alternative to surgical excision. ( J Am Acad Dermatol
2015;73:645-54.)
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CNS: central nervous system
IL: interleukin
MDS: myelodysplastic syndromeA
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646 Shi et alpatients has been surgical excision with or without
radiation. Recurrences with these therapies are com-
mon. Newer systemic therapies including BRAF in-
hibitors and monoclonal antibodies directed against
CTLA4 and PD-1 are revolutionizing themanagement
of metastatic melanoma, but complete responses are
rare and their role in the management of cutaneous-CAPSULE SUMMARY
d Intralesional interleukin (IL)-2 is now
recognized by National Comprehensive
Cancer Network as a potential treatment
for advanced melanoma.
d We present a large case series of patients
treated with intralesional IL-2 combined
with topical imiquimod and retinoid.
d With a 100% complete response rate, the
presented regimen is a promising option
for patients with advanced melanoma.only metastatic disease is
unclear.2 Intralesional inter-
leukin (IL)-2, however, has
the highest reported com-
plete response rate of any
melanoma therapy.2 One
phase II clinical trial demon-
strated a complete response
rate of 85%3 and studies from
Europe and Canada have also
demonstrated excellent com-
plete response rates.3-7 This
therapy also appears to be
relatively safe; to date there
have been no reports of
vascular leak syndrome or
any of the other severe toxicities commonly associ-
ated with intravenous systemic IL-2.2,8
Herein we report a 100% complete local response
rate in 11 patients with cutaneous metastatic mela-
noma treated with intralesional IL-2 concomitantly
with the proinflammatory immune modulator, imi-
quimod, and a topical retinoid, which was added to
enhance the penetration of the imiquimod. We
hypothesized that combining intralesional IL-2 with
imiquimod (which has been used for the treatment of
melanoma in situ with anecdotal success) and a
topical retinoid may increase the complete response
rates seen with IL-2 monotherapy.
METHODS
After obtaining approval from the institutional
review board, a retrospective review of the elec-
tronic medical records of patients seen in the
department of dermatology between 2006 and 2015
was performed. Inclusion criteria consisted of a
diagnosis of stage III or IV melanoma and a history
of intralesional IL-2 therapy combined with imiqui-
mod and a topical retinoid.
Patients
Patient demographic information, medical his-
tory, treatment course and associated toxicities, and
posttreatment monitoring are summarized in Tables I
and II. The mean age at time of presentation for
intralesional IL-2 therapy was 69 (range 54-90) years.
The majority of patients (8 of 11) had stage III
melanoma caused by cutaneous in-transit metastaseswith or without a positive sentinel lymph node. The
remaining 3 patients had stage IV melanoma at the
time of initiating IL-2 therapy. All patients had 1 or
more chronic medical conditions. Notably, 64% had
significant cardiovascular disease. Two patients had
melanoma-unrelated advancedmyelodysplastic syn-
drome (MDS), one requiring regular blood trans-fusions and the other weekly
injections of granulocyte
colony-stimulating factor.
Ten of the 11 patients had a
history of local recurrence
after surgical excision of their
cutaneous melanoma metas-
tases. Patient 2 was no longer
a surgical candidate because
of multiple comorbidities;
patient 4 had multiple meta-
static tumors on the scalp and
was referred by surgical
oncology for neoadjuvant in-
tralesional IL-2 therapy
before surgical excision.Several patients had failed a variety of nonsurgical
treatments before being started on intralesional IL-2.
These included dacarbazine (patient 1), carboplatin/
paclitaxel (patient 11), vemurafenib (patient 1), ra-
diation (patients 2, 5, 6, and 11), intralesional BCG
(patient 5), and dendritic cell vaccination using
melanoma antigens (patient 8).
Treatment
IL-2 solution was prepared by dissolving alde-
sleukin powder (containing 22 million IU of IL-2 and
buffer) in 1.2 mL of sterile saline by pharmacy.
Patients 2 to 10 received a testing dose between 3
and 7 million IU and then were escalated to 15 to 22
million IU biweekly. Treatment was continued for 4
to 6 weeks depending on the patient’s tolerance to
therapy and clinical response.
All patients were also treated with daily topical
imiquimod and a retinoid cream, usually 0.1%
tazarotene, to all tumors including a 10-cm periph-
eral margin when possible. Patients 1, 7, and 8
initially had tumors limited to the extremities and
overnight occlusive wraps were used in these cases
to increase cutaneous absorption of the topical
medications. The frequency of topical therapy was
reduced to 5 times weekly once the treated sites had
become intolerably erythematous and inflamed. For
lesions that ulcerated during treatment, topical
therapies were either temporarily discontinued or
their frequency was reduced. After completion of
intralesional therapy, topical medications were
applied daily for 7 days each month for a period of
Table I. Patient demographics, comorbidities, and tumor characteristics
Patient
Age, y/sex
(treatment year)
Chronic medical conditions
at start of IL-2 therapy Primary melanoma
First
metastasis Stage
Size of largest
met and number*
1 54/F (2013) HTN, HL, hypothyroidism 2007, Left forearmy October 2012 IV S2, N1 (9 cm, 1)
2 88/M (2014) NMSC, pulmonary fibrosis,
CAD, CHF, prostate cancer,
gout, hypothyroidism
October 2013, top
front scalp
December 2013 III S1, N1 (\1 cm, 3)
3 79/M (2011) MDS,z splenomegaly, CHF January 2011, scalp March 2011 III S1, N3 (\1 cm,[20)
4 63/M (2011) Multiple NMSC, HL, type-2
diabetes, prostate cancer
s/p prostatectomy 2007
November 2010,
right scalp
January 2011 III S2, N1 (1.3 cm, 4)
5 55/M (2006) HTN, HL, CAD, multiple
myocardial infarctions
(s/p coronary artery stenting),
papillary thyroid carcinoma
(s/p thyroidectomy and I-131
ablation), chronic edema,
asthma
June 2006, left
facial temporal
region
May 2007 IV S2, N3 (8.5 cm, 20)
6 80/M (2013) MDS, melanomas, HTN,
valvular heart disease
November 2009,
right cheek
January 2012 IV S2, N3 (3 cm,[60)
7 46/F (2011) Hypothyroidism, interstitial
lung disease
2005, right calf February 2011 III S2, N2 (1.7 cm, 5-6)
8 89/M (2011) Interstitial lung disease, HTN,
BPH, CAD s/p CABG, CVA
July 2003, right
forearm
May 2004 III S3, N3 (18 cm, 21)
9 56/M (2008) C5 injury resulting in spastic
paresis, HTN, chronic
postoperative left leg edema
June 2007, left
plantar foot
September 2008 III S2, N3
10 90/M (2010) 3 Primary melanoma s/p excision
in 2000, 2005, 2008 (4-mm
right forearm), CAD with
multiple MIs s/p CABG and
cardiac stenting, CHF with
persistent leg edema, AFib,
HTN, DM, giant cell arteritis,
polymyalgia rheumatic
September 2008,
right forearm
January 2010 III
11 64/M (2011) Crohn’s disease, HTN, BPH June 2011, right ear June 2012 III S1, N2
AFib, Atrial fibrillation; BPH, benign prostate hyperplasia; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF,
congestive heart failure; CVA, cerebral vascular accident; DM, diabetes mellitus; F, female; HL, hyperlipidemia; HTN, hypertension; IL,
interleukin; M, male; MDS, myelodysplastic syndrome; met, metastasis; MI, myocardial infarction; NMSC, nonmelanoma skin cancer; s/p,
status-post.
*Size of largest tumor: S1,#1 cm; S2, 1.1-9 cm; S3, 9.1-20 cm. Number of cutaneous and subcutaneous tumors present: N1, #5; N2, 6-19; N3,
$20.
yBRAF-V600E mutation positive.
zTransfusion-dependent MDS before diagnosis of metastatic melanoma.
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modified treatment course. For example, patient 9
continued topical therapy only for an additional
7 weeks before discontinuing it completely.
RESULTS
Treatment outcome and clinical course
Patients were monitored for melanoma recur-
rence with frequent clinical examinations and all
patients except patients 1 and 3 received positron
emission/computed tomography scans at various
intervals. Average follow-up time was 24 (range 5-
47) months. All patients achieved complete clinicalresponse to the treated lesions within 1 to 3 months
of initiating intralesional IL-2. The 2-year survival
was 82%. Seven of 11 patients are still living without
recurrence of melanoma. Of the 5 deaths, 3 were
caused by complications from visceral or central
nervous system (CNS) metastases, 1 died of natural
causes at age 94 years, and 1 patient died of his MDS.
Patient 1 had remarkable response of her 9-cm
tumor within 2 months after only 2 injections. She
declined further treatments because of increased
burden of her visceral disease and transportation
difficulties. She is currently living with progressive
metastatic disease and has restarted chemotherapy.
Table II. Treatment course and follow-up
Patient
Treatments
before IL-2
Initial
treatment
Treatment
site(s); no.
of injections;
treatment
dose; duration
Treatment-
related
adverse
events*
Additional
and/or
adjunctive
therapyy
Clinical
response to
IL-2 therapy
Rebiopsy
ratio,
positive/
negative
Follow-up
since
start of
IL-2, mo
Clinical
recurrence
of treated
lesions
Last
examination
Current
status
1 Dacarbazine,
vemurafenib,
radiation
1-wk prior
July
2014
Left forearm
(1 site); 2
injections; 7
million IU; 1 wk
Nausea,
worsening
of existing
depression
Nonez Complete
response at
2 mo
Not done 5 Yesx January
2014
Living, with wors-
ening metastatic
disease; re-
started on
chemotherapy
(dabrafenib
and trametinib)
2 None December
2014
Front and vertex
scalp; 9
injections; 7-15
million IU; 9 wk
Asymptomatic
hypotension,
mild rigors
None Complete
response at
3 mo
0/2 11 No October
2014
Living without
recurrence
3 Excision{ May
2011
Scalp; 29
injections; 5-10
million IU; 32 wk
None None Complete
response at
2 mo
1/16k 10 No May
2012
Died in May 2012
of complications
of MDS
4 None June
2011
Scalp; 30
injections; 7-22
million IU; 23 wk
Rigors and chills
within 4 h of
injection, fa-
tigue, injection-
site panniculitis
Excision for
histologic
confirmation
of complete
resolution
Complete
response
at 6 wk
0/4 47 No January
2015
Living without
recurrence
5 Wide local
excision, left
superficial
parotidectomy
and modified
radical neck
dissection,
intensive
hyperfrac-
tionated
radiation,
intralesional
live BCG 3 3
rounds
April
2010
Left face
and neck;
38 injections;
3.6-22
million IU;
34 wk
Rigors and
arthralgia 3-6 h
after therapy,
loss of 10%
body weight,
fatigue lasting
1 d after each
treatment,
treatment-site
ulcerations,
sclerosis over
sites of repeated
injection, sensi-
tization to IL-2
preparation#
Cryotherapy to
recurrent ear
lesions; vemura-
fenib August
2012; right
temporal CNS
metastasis s/p
stereotactic
radiosurgery
September 17,
2012; whole
brain radiation
(after devel-
oping new
cranial mets);
surgical excision
of recurrent
lesions
Complete
response
at 6 mo**
0/10 32 Yes** September
2012
Died in
November
2012 of
complications
of brain
metastasesyy
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6 Excision,
radiation
November
2013
Scalp, temples,
and left
preauricular
regions; 16
injections;
7-14 million IU;
10 wk
Chills, rigor
within 4-6 h
after injection,
granulomatous
dermatitis
and ulcers at
injection site
Excisions of
untreated
sites
Complete
response to
treated
lesions, but
continued
to develop
multiple new
in-transit
metastases
0/2 25 No February
2015
Living without
recurrence
7 Excision 3 2
(once of
initial tumor,
then again of
recurrence)
March
2011
Right lower
extremity;
41 injections;
7-22 million IU;
72 wk
Mild chills, leg
ulceration,
injection-site
granulomatous
dermatitis and
panniculitis
Nonez Complete
response at
2 mo
0/8 46 No January
2015
Living without
recurrence
8 Wide local
excision,
dendritic cell
vaccination
using
melanoma
antigens
November
2011
Right
forearm;
7 injections;
7 million IU;
4 wk
Transient
dyspnea
within 4 h of
seventh
treatment,zz
asymptomatic
hypotension
Cryotherapy
to 1 IL-2-
treated sitez
Complete res-
ponse within
1 mo; develo-
ped 1 meta-
static lesion
proximal to
treatment
area, which
was excised
then treated
topically with
imiquimod
and retinoids
0/9 31 No July
2014
Living
without
recurrence
9 Interferon
3 9 mo,
excisions of
metastatic
tumors along
left leg and
thigh,
complete
LN dissection
December
2008
Left plantar
foot, medial
thigh, and
groin; 16
injections;
6-18 million
IU; 28 wkxx
Numerous ice
pickelike
scars at
injection
sites
Continued topical
treatment for
7 wk after all
metastatic
tumors
regressed; palli-
ative gamma
knife radio-
surgery to brain
metastatic
tumors
Complete
response
within 3 mo;
developed LN
and CNS
metastasis
18 mo later
0/4 28 No March
2009
Died in April
2011 of
complications
of brain
metastases
10 Excision February
2010
Right forearm; 9
injections; 3-11
million IU; 3 wkxx
Decreased
appetite (per
daughter)
None Complete
response
within 4-8 wk
0/1 24 No January
2012
Died in 2012 of
natural
causes
Continued
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Table II. Cont’d
Patient
Treatments
before IL-2
Initial
treatment
Treatment
site(s); no.
of injections;
treatment
dose; duration
Treatment-
related
adverse
events*
Additional
and/or
adjunctive
therapyy
Clinical
response to
IL-2 therapy
Rebiopsy
ratio,
positive/
negative
Follow-up
since
start of
IL-2, mo
Clinical
recurrence
of treated
lesions
Last
examination
Current
status
11 Excision, SLNB
(1 positive
node), resec-
tion of local
recurrence
with right
parotid/neck
dissection and
skin graft,
carboplatin/
paclitaxel after
local recur-
rence, local
radiation
(right earx),
topical
imiquimod 2
mo before IL-2
January
2014
Right ear;
10 injections;
7 million IU;
5 wk
Rigors and
fever 4-6 h
after
injections
(improved
by fourth
week of
treatment),
nausea
None{{ Complete
response
within 4-6 wk;
developed
pulmonary,
hepatic, and
osseous
metastases
8 mo after
initiating IL-2
Not
done
8 No September
2014
Died in
October
2014 of
complications
of visceral
metastases
CNS, Central nervous system; IL, interleukin; LN, lymph node; MDS, myelodysplastic syndrome; SLNB, sentinel lymph node biopsy; s/p, status-post.
*All treated sites had depigmentation and hypopigmentation.
yAll patients received concurrent topical imiquimod and retinoid creams to IL-2 treatment sites.
zOcclusion wrap applied after topical imiquimod and retinoid creams.
xPatient declined further treatment because of increased burden of visceral metastasis and difficulty with transportation. She later developed numerous satellite lesions in proximity of the
treatment site.
{Local recurrence occurred within 1 mo postexcision.
kOne of 8 biopsied sites were positive for residual melanoma at 1 mo posttreatment; 0/8 biopsied sites were positive at 2 mo posttreatment.
#Immediate urticarial within minutes of IL-2 injection over left ear tumor. Biopsy specimen showed sparse perivascular eosinophils and neutrophils, consistent with urticarial reaction, likely because
of sensitization from IL-2 preparation. Treatment over this site was discontinued.
**Durable response with resolution of all treated sites achieved between April and October 2012. Patient decided to stop topical imiquimod and retinoid cream because of clinical resolution and
unremarkable positron emission/computed tomography in April 2012. In October 2012, he developed multiple new metastatic lesions on the front of neck and scalp that was confirmed on positron
emission/computed tomography.
yyOncology follow-up in September 2012 showed stable disease without clinical progression of metastasis. In November 2012 patient developed acute altered mental status and brain computed
tomography showed multiple new intracranial metastasis. Patient died in hospice within the same month.
zzPatient presented to emergency department and had normal oxygen saturation. Chest x-ray showed chronic pulmonary fibrosis without acute pulmonary edema. His dyspnea thought to be
exacerbation of intrinsic interstitial lung disease, unlikely a result of IL-2 induced pulmonary edema.
xxTreated with IL-2 until treated tumor sites entirely regressed.
{{Imiquimod daily treatment was started 2 mo before IL-2 initiation. During IL-2 treatment course, daily topical imiquimod and topical tretinoin 0.1% cream were applied to the treatment areas.
Topical treatments were temporarily stopped after the fourth IL-2 treatment and held for a period of 2 wk to allow the exuberant inflammatory response and ulceration to improve. After the ninth
treatment with IL-2, imiquimod and retinoid cream were restarted as maintenance dosing for the first week of each month (daily application for 7 d).
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Shi et al 651Her excellent response to intralesional IL-2 may have
been augmented by the prior radiation therapy she
received to the tumor, which has been reported to
synergize with IL-2 therapy.9
Patient 2 had a complete response within
3 months with resolution of all 3 tumors located on
his scalp. He is currently living without recurrence.
Patient 4 underwent surgical excision with
lymphatic mapping after completing 39 injections
within a 2-month period for his scalp metastases.
After therapy both the excised skin and sentinel
lymph node biopsy specimen were negative for
melanoma.
Patient 5 had a 6-month durable response. He self-
discontinued topical treatments after repeated bi-
opsy specimens and a follow-up positron emission/
computed tomography failed to detect residual or
new tumors. He developed a cutaneous recurrence
6 months later with multiple tumors on the front of
his neck and scalp. Although his recurrent melanoma
initially resolved with a second round of intralesional
IL-2 (Fig 1), he developed widespread metastatic
osseous, pulmonary, hepatic, and CNS disease, and
died of complications of his CNS metastasis.
Patient 6 had complete clinical resolution of all
treated lesions, but continued to develop multiple
new in-transit metastases in the head and neck
region. He underwent additional excisions and is
now living disease-free.
Patient 8 developed self-limited dyspnea 4 hours
after his seventh injection, necessitating discontinu-
ation of IL-2. Nevertheless, he had a complete
response to therapy (Fig 2). A single in-transit
metastasis outside of his IL-2 treatment area was
treated with excision followed by topical imiquimod
and tazarotene. He is now living without recurrence.
Patient 9 had clinical resolution of more than 100
lesions within 3 months of initiating IL-2 therapy but
developed nodal and CNS metastasis 18 months later
and died from complications of brain metastases.
Patient 11 had clinical resolution of all lesions
within 4 to 6 weeks but then died of pulmonary,
hepatic, and osseous metastases 8 months later.
Patients 3, 7, 8, and 10 had uncomplicated
posttreatment courses without recurrence. Patient 3
eventually died from complications of his MDS at age
80 years. Patient 10 eventually died of natural causes
at age 94 years.
Histologic findings
Punch biopsy specimens of selected treated
sites were performed on patients 2 through 11 to
confirm response (mean 5.1 biopsy specimens/
patient). Permanent sections were stained with
hematoxylin-eosin and read by a board-certifieddermatopathologist for evidence of residual mela-
noma. Melanocyte-specific stains (Melan-A and
HMB-45) were added when appropriate to confirm
regression of melanoma cells. Patient 3 had 1 of 8
treated scalp sites showing residual melanoma at
1 month of therapy but after completing 2 months all
sites were devoid of residual melanoma.
Representative biopsy specimens from patient 5 are
shown in Fig 1. Dermal melanophages and melanin
incontinence were common findings in posttreat-
ment biopsy specimens. Patient 4 developed a
granulomatous dermatitis at a treatment site.
Patients 4, 7, and 9 developed focal panniculitis,
which resolved spontaneously.Treatment related toxicities
Treatment toxicities were mild to moderate.
Patients 2, 4, 5, 6, 7, and 11 had rigors within 3 to
6 hours after injections, which typically lasted for 15
to 30 minutes and then self-resolved. Patient 1
developed nausea but declined treatment with
ondansetron. She also reported worsening of her
baseline depression. Patient 2 developed asymptom-
atic hypotension (systolic blood pressure decreased
from baseline of 140s mmHg to 100s mmHg) and his
antihypertensive medications were held on subse-
quent treatment days. Intralesional IL-2 therapy was
discontinued in patient 5 after several months
because of the development of local urticaria at
treatment sites. Patient 7 who had interstitial lung
disease developed shortness of breath 4 hours after
her seventh injection (7 million IU). Although he was
found to have a normal oxygen-saturation and his
chest x-ray was unchanged from baseline, IL-2 was
discontinued. Patient 10 developed decreased appe-
tite during his treatment course, according to his
daughter, but he self-reportedly felt well. Patient 7
required surgical debridement of necrotic tissue
resulting from intralesional therapy.DISCUSSION
Treatment of cutaneous melanoma metastases
with intralesional IL-2 in combination with topical
imiquimod and a retinoid cream resulted in a com-
plete clinical local response in 11 patients with stage
III and IV disease. The majority of our patients were
elderly with significant comorbidities, rendering
them poor candidates for other treatment modalities,
and many of them had metastatic disease and prior
treatment failures. The 2-year survival after first
metastasis was 82%. Patients with 20 or more
metastatic lesions (N2) did not have poorer out-
comes than those with less than 20 metastases (N1
and N2). The favorable outcomes in these patients
Fig 1. Cutaneous melanoma: clinical and histologic comparisons before and after treatment
with intralesional interleukin 2 in combination with topical imiquimod and a retinoid cream.
A and B, Before treatment, a large melanoma encompassing most of the right forearm of an 89-
year-old man (patient 8). This same arm during (C) and 31 months after (D) immunotherapy,
demonstrating a depigmented arm. Biopsy specimens of this site reveal some residual pigment
within melanophages but no active melanoma. E, Hematoxylin-eosin staining of a biopsy
specimen taken before initiation of immunotherapy (patient 5) reveals numerous atypical
melanocytes within the dermis. These melanocytes have prominent nucleoli (thin arrow)
and an increased nuclear to cytoplasmic ratio (broad arrow). (Original magnification: 3400.)
F, A posttreatment biopsy specimen from the same patient reveals the absence of atypical
melanocytes and the presence of melanophages (arrow) within a background of fibrin necrosis
and degenerated collagen. A mixed infiltrate with neutrophils, histiocytes, and lymphocytes is
also seen. Dusky melanin pigment is present within the melanophages (arrow). G, Melan-A
staining of the biopsy specimen (shown in F) fails to detect atypical melanocytes.
J AM ACAD DERMATOL
OCTOBER 2015
652 Shi et al
Fig 2. Metastatic melanoma: positron emission tomographic (PET)/computed tomography
(CT) images. A-C, PET/CT of the head and neck after recurrence of malignant melanoma
reveals increased FDG uptake spanning from the nose, left malar cheek, to the left ear, which
represents a large melanoma (8.5 cm) and multiple additional in-transit metastases. E-G, Three
months after restarting intralesional interleukin 2, imiquimod, and a topical retinoid, there is
resolution of the enhancing lesions. D, At initial presentation, PET/CT image (patient 8) shows
increased FDG uptake in the skin and subcutaneous tissues of the back of right forearm,
consistent with biopsy-proven melanoma (18- 3 6-cm plaque). H, At 5 months posttreatment,
no hypermetabolic lesion is identified.
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regimen may have a survival benefit.
The treatment regimen reported herein is distinct
in that concomitant topical imiquimod and a retinoid
cream was used in conjunction with intralesional IL-
2. Each of these medications has a unique mecha-
nism of action. IL-2 is thought to work via its ability to
directly induce proliferation and activation of T cells,
B cells, and lymphokine-activated killer cells, which
in turn can directly lyse tumor cells.10 Through its
interaction with toll-like receptors 7 and 8, imiqui-
mod induces production of tumor necrosis factor,
interferon-a, and IL-12, which have anticancer prop-
erties.11 Imiquimod is also known to activate and
recruit plasmacytoid dendritic cells and to promote
cytotoxic T-cell responses.12 Retinoids influence
lymphocyte differentiation and keratinocyte matura-
tion, but whether or not they possess antimelanoma
properties is unknown. One possibility is that topical
retinoids can increase the epidermal penetration of
imiquimod, enhancing its inflammatory response.13
It is unclear why intralesional IL-2 has a superior
complete response rate when compared with intra-
venous IL-2. It is likely that the direct administrationof the medication into the tumor and higher local
concentration imparts some of this benefit. Weide
et al6 reported that patients with melanoma treated
with intralesional IL-2 have increased circulating
antimelanoma T cells. Green et al14 noted that
intralesional IL-2 in combination with topical imi-
quimod can increase the CD4/CD8 ratio and increase
interferon-g secretion by peripheral blood mono-
nuclear cells. Interestingly, in our case series, 2
patients with MDS achieved complete local re-
sponses, suggesting that tissue resident immune cells
may have played a dominant role in tumor regres-
sion, as these patients were deficient in circulating
immune cells.
One limitation of our study is that peripheral
blood samples were not collected. In future studies it
will be essential to determine if the relatively low
doses of administered IL-2 induces the expansion of
circulating T-regulatory cells,15 as such cells might
promote growth of internal metastases.
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